The safety and efficacy of ferumoxytol in the treatment of iron deficiency: a systematic review and meta-analysis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Ferumoxytol is an intravenous (IV) iron formulation for treatment of iron deficiency (ID) that faced post-marketing reports of serious adverse events (SAEs).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Transfusion

Title: Transfusion

Publisher: Wiley

ISSN (Electronic): 1537-2995

ISSN (Print): 0041-1132

Publication date (Electronic): December 2019

Volume: 59

Issue: 12

Affiliations

[1 ] Division of Hematology, Department of Medicine, University Healthy Network, Toronto, Ontario, Canada.

[2 ] Hematology Oncology Clinical Research Group, St. Michael's Hospital, Toronto, Ontario, Canada.

[3 ] Department of Medicine, Georgetown University School of Medicine, Washington DC, USA.

[4 ] Auerbach Hematology and Oncology, Baltimore, Maryland, USA.

[5 ] McMaster University, Hamilton, Ontario, Canada.

[6 ] Division of Hematology, Department of Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.

[7 ] Department of Laboratory Medicine and Pathobiology, St. Michael's Hospital, Toronto, Ontario, Canada.

[8 ] Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.

Article

DOI: 10.1111/trf.15587

PubMed ID: 31762068

SO-VID: 6ed6b720-98a5-4e7d-8932-806c9ef294a6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 4

See all cited by